NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Nuscience Peptides

Published 12 Nov 2026. 35-page investigative report on who is behind Nuscience Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 49 Finnrick lab tests, NuScience Peptides posts a 39% overall pass rate, with 19 pass / 30 fail. The spread is not uniform: GHK-Cu is the cleanest small-sample signal and tirzepatide is the strongest GLP signal, while CJC-1295 and Melanotan II are the weak side. Because ratings move under stricter purity and fill grading, this is a current-lot vendor, not a blind-trust vendor.

The identity trail is unusually concrete for this market: USPTO records, FDA correspondence and ad-transparency data tie the brand to named managers, a New Mexico LLC signal and a North Carolina operating address. The missing layer is technical control: no public source reviewed identifies the manufacturer, supplier country, QA director or batch-release authority.

The investigation's sharper finding is document and channel control. Production has removed the sensitive GLP pages, while a public staging clone still exposes GLP catalog pages, a peptide calculator, cart flow and login-gated checkout. Lab records exist at Freedom Diagnostics, MZ Biolabs and Chromate, but the vendor page shows only a curated subset; the full report traces unpublished GLP COAs, cross-product lot reuse and cap-colour lot identifiers.

Inside the full report:

  • Per-product pass/fail rates, rating trajectories and methodology-divergence charts for all 10 tested products
  • COA-provenance audit comparing the live lab page with Freedom Diagnostics, MZ Biolabs and Chromate records
  • Lot-traceability exhibits covering cross-product numeric lots and cap-colour identifiers
  • Production-versus-staging storefront diff, cart screenshots and checkout-gate observations
  • Corporate, trademark, address-cluster, ad-transparency and payment-rail analysis, including unresolved leads
  • Narrow analysis of the 2016 SEC judgment and its document-reliance implications

Risk assessment

  • Off-canonical storefront and brand-confusion risk — high: Production pages are 404, but staging2 publicly lists GLP-3 RT, GLP-1 Sema, GLP-2 Tirz, survodutide, mazdutide, PT-141, tesamorelin and BAC water with cart/login checkout; actual fulfillment is unverified.
  • COA traceability risk — high: 91 Freedom COAs versus 49 vendor-published documents; all 32 GLP Freedom records unpublished; lot 008412 spans tirzepatide/retatrutide and cap-colour lots appear in October 2026.
  • Product-quality risk — CJC-1295 and Melanotan II — high: Finnrick shows CJC-1295 at 0 pass / 3 fail with a 25.99% rating and Melanotan II at 1 pass / 6 fail with a 47.13% rating.
  • Product-quality risk — mixed/test-first products — medium: Semaglutide, retatrutide, BPC-157, ipamorelin, mazdutide and PT-141 show mixed or small-sample Finnrick records; verify the current lot rather than buying blind.
  • Payment-recourse risk — medium: Live checkout uses custom gateways plus OpenNode and staging uses Onvo; the merchant of record is not disclosed and account-gated checkout limits buyer recourse.